Advertisement

Surgery for EG Junction Cancer

  • Yasuyuki SetoEmail author
  • Hiroharu Yamashita
  • Susumu Aikou
Chapter

Abstract

Should esophagogastric junction (EGJ) cancer be classified or managed as gastric cancer or esophageal cancer or else? The debate focused on the issue has still remained [1], though EGJ cancer is increasing worldwide, in Asia [2–5] as well as western countries [6–8]. Squamous cell carcinoma developed in EGJ region is unanimously treated as esophageal cancer. For EGJ adenocarcinoma, Siewert classification has been widely applied: type I (adenocarcinoma of the distal esophagus), tumors with an epicenter located more than 1 cm above the EGJ; type II (true cardia cancer), tumors with an epicenter located within 1 cm oral and 2 cm aboral from the EGJ; and type III (subcardial cancer), tumors with an epicenter located below 2 cm from the EGJ [9, 10]. Among Siewert classifications, Siewert type I and III tumors are usually managed like esophageal and gastric cancers, respectively. However, in 7th AJCC TNM classification, both Siewert type II and III tumors had been classified as esophageal cancer. After some discussions [11–13], in 8th version, type III was changed to gastric cancer classification, while type II still stays in esophageal classification [14–15]. There have been many papers regarding the clinicopathologic features of Siewert type II tumors to identify the pathogenesis and appropriate treatment strategy. Some papers showed that the characteristics of Siewert type II were quite similar with gastric cancers [11, 12]. However, some papers reported that there were two distinct pathways of tumorigenesis of EGJ adenocarcinoma, related or unrelated to intestinal metaplasia, gastric atrophy, and gastric acid secretion [16–17]. The etiology as well as the treatment strategy has still remained controversy, especially for Siewert type II tumors.

Supplementary material

Video 20.1

(MPG 453634 kb)

Video 20.2

(MPG 476386 kb)

References

  1. 1.
    Van Laethem JL, Carneiro F, Ducreux M, Messman H, Lordick F, Ilson DH, Allum WH, Haustermans K, Lepage C, Matysiak-Budnik T, Cats A, Schmiegel W, Cervantes A, Van Cutsem E, Rougier P, Seufferlein T. The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona. Dig Liver Dis. 2016;48(11):1283–9.  https://doi.org/10.1016/j.dld.2016.08.112. Epub 2016 Aug 20CrossRefPubMedGoogle Scholar
  2. 2.
    Wang K, Yang CQ, Duan LP, Yang XS, Xia ZW, Cui RL, Jin Z, McNutt M. Changing pattern of adenocarcinoma of the esophagogastric junction in recent 10 years: experience at a large tertiary medical center in China. Tumori. 2012;98(5):568–74.  https://doi.org/10.1700/1190.13196.CrossRefPubMedGoogle Scholar
  3. 3.
    Liu K, Yang K, Zhang W, Chen X, Chen X, Zhang B, Chen Z, Chen J, Zhao Y, Zhou Z, Chen L, Hu J. Changes of esophagogastric junctional adenocarcinoma and gastroesophageal reflux disease among surgical patients during 1988–2012: a single-institution, high-volume experience in China. Ann Surg. 2016;263(1):88–95.  https://doi.org/10.1097/SLA.0000000000001148.CrossRefPubMedGoogle Scholar
  4. 4.
    Hatta W, Tong D, Lee YY, Ichihara S, Uedo N, Gotoda T. Different time trend and management of esophagogastric junction adenocarcinoma in three Asian countries. Dig Endosc. 2017;29(Suppl 2):18–25.  https://doi.org/10.1111/den.12808.CrossRefPubMedGoogle Scholar
  5. 5.
    Koizumi S, Motoyama S, Iijima K. Is the incidence of esophageal adenocarcinoma increasing in Japan? Trends from the data of a hospital-based registration system in Akita Prefecture, Japan. J Gastroenterol. 2017;  https://doi.org/10.1007/s00535-017-1412-4. [Epub ahead of print]CrossRefGoogle Scholar
  6. 6.
    Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008;100(16):1184–7.  https://doi.org/10.1093/jnci/djn211. Epub 2008 Aug 11CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomark Prev. 2010;19(6):1468–70.  https://doi.org/10.1158/1055-9965.EPI-10-0012. Epub 2010 May 25CrossRefGoogle Scholar
  8. 8.
    Buas MF, Vaughan TL. Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol. 2013;23(1):3–9.  https://doi.org/10.1016/j.semradonc.2012.09.008.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Siewert JR, Hölscher AH, Becker K, Gössner W. Cardia cancer: attempt at a therapeutically relevant classification. Chirurg. 1987;58(1):25–32. Chirurg 2003 Aug;74(8):703–8PubMedGoogle Scholar
  10. 10.
    Stein HJ, von Rahden BH, Höfler H, Siewert JR. Carcinoma of the oesophagogastric junction and Barrett’s esophagus: an almost clear oncologic model? Chirurg. 2003;74(8):703–8.CrossRefGoogle Scholar
  11. 11.
    Suh YS, Han DS, Kong SH, Lee HJ, Kim YT, Kim WH, Lee KU, Yang HK. Should adenocarcinoma of the esophagogastric junction be classified as esophageal cancer? A comparative analysis according to the seventh AJCC TNM classification. Ann Surg. 2012;255(5):908–15.  https://doi.org/10.1097/SLA.0b013e31824beb95.CrossRefPubMedGoogle Scholar
  12. 12.
    Mullen JT, Kwak EL, Hong TS. What’s the best way to treat GE junction tumors? Approach like gastric cancer. Ann Surg Oncol. 2016;23(12):3780–5. Epub 2016 Jul 26CrossRefGoogle Scholar
  13. 13.
    Adeshuko FA, Squires MH, Poultsides G, Pawlik TM, Weber SM, Schmidt C, Votanopoulos K, Fields RC, Maithel SK, Cardona K. A multi-institutional study comparing the use of the American joint committee on cancer 7th edition esophageal versus gastric staging system for gastroesophageal junction cancer in a Western population. Am Surg. 2017;83(1):82–9.PubMedGoogle Scholar
  14. 14.
    Rice TW, Patil DT, Blackstone EH. 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg. 2017;6(2):119–30.  https://doi.org/10.21037/acs.2017.03.14.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Rice TW, Gress DM, Patil DT, Hofstetter WL, Kelsen DP, Blackstone EH. Cancer of the esophagus and esophagogastric junction-major changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(4):304–17.  https://doi.org/10.3322/caac.21399. Epub 2017 May 26CrossRefPubMedGoogle Scholar
  16. 16.
    Nunobe S, Nakanishi Y, Taniguchi H, Sasako M, Sano T, Kato H, Yamagishi H, Sekine S, Shimoda T. Two distinct pathways of tumorigenesis of adenocarcinomas of the esophagogastric junction, related or unrelated to intestinal metaplasia. Pathol Int. 2007;57(6):315–21.CrossRefGoogle Scholar
  17. 17.
    Horii T, Koike T, Abe Y, Kikuchi R, Unakami H, Iijima K, Imatani A, Ohara S, Shimosegawa T. Two distinct types of cancer of different origin may be mixed in gastroesophageal junction adenocarcinomas in Japan: evidence from direct evaluation of gastric acid secretion. Scand J Gastroenterol. 2011;46(6):710–9.  https://doi.org/10.3109/00365521.2011.565069.. Epub 2011 Mar 30CrossRefPubMedGoogle Scholar
  18. 18.
    Mariette C, Piessen G, Briez N, Gronnier C, Triboulet JP. Oesophago-gastric junction adenocarcinoma: which therapeutic approach? Lancet Oncol. 2011;12(3):296–305.  https://doi.org/10.1016/S1470-2045(10)70125-X.. Epub 2010 Nov 23CrossRefPubMedGoogle Scholar
  19. 19.
    Jezerskyte E, van Berge Henegouwen MI, Cuesta MA, Gisbertz SS. Gastro-esophageal junction cancers: what is the best minimally invasive approach? J Thorac Dis. 2017;9(Suppl 8):S751–S60.  https://doi.org/10.21037/jtd.2017.06.56.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Haverkamp L, Seesing MF, Ruurda JP, Boone J, V Hillegersberg R. Worldwide trends in surgical techniques in the treatment of esophageal and gastroesophageal junction cancer. Dis Esophagus. 2017;30(1):1–7.  https://doi.org/10.1111/dote.12480.CrossRefPubMedGoogle Scholar
  21. 21.
    Martin JT, Mahan A, Zwischenberger JB, McGrath PC, Tzeng CW. Should gastric cardia cancers be treated with esophagectomy or total gastrectomy? A comprehensive analysis of 4,996 NSQIP/SEER patients. J Am Coll Surg. 2015;220(4):510–20.  https://doi.org/10.1016/j.jamcollsurg.2014.12.024. Epub 2014 Dec 29CrossRefPubMedGoogle Scholar
  22. 22.
    Giacopuzzi S, Bencivenga M, Weindelmayer J, Verlato G, de Manzoni G. Western strategy for EGJ carcinoma. Gastric Cancer. 2017;20(Suppl 1):60–8.  https://doi.org/10.1007/s10120-016-0685-2. Epub 2016 Dec 30CrossRefPubMedGoogle Scholar
  23. 23.
    Blank S, Schmidt T, Heger P, Strowitzki MJ, Sisic L, Heger U, Nienhueser H, Haag GM, Bruckner T, Mihaljevic AL, Ott K, Büchler MW, Ulrich A. Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach? Gastric Cancer. 2018;  https://doi.org/10.1007/s10120-017-0746-1. [Epub ahead of print].CrossRefGoogle Scholar
  24. 24.
    Kneuertz PJ, Hofstetter WL, Chiang YJ, Das P, Blum M, Elimova E, Mansfield P, Ajani J, Badgwell B. Long-term survival in patients with gastroesophageal junction cancer treated with preoperative therapy: do thoracic and abdominal approaches differ? Ann Surg Oncol. 2016;23(2):626–32.  https://doi.org/10.1245/s10434-015-4898-0. Epub 2015 Nov 12CrossRefPubMedGoogle Scholar
  25. 25.
    Fuchs H, Hölscher AH, Leers J, Bludau M, Brinkmann S, Schröder W, Alakus H, Mönig S, Gutschow CA. Long-term quality of life after surgery for adenocarcinoma of the esophagogastric junction: extended gastrectomy or transthoracic esophagectomy? Gastric Cancer. 2016;19(1):312–7.  https://doi.org/10.1007/s10120-015-0466-3. Epub 2015 Jan 28CrossRefPubMedGoogle Scholar
  26. 26.
    Sugita S, Kinoshita T, Kaito A, Watanabe M, Sunagawa H. Short-term outcomes after laparoscopic versus open transhiatal resection of Siewert type II adenocarcinoma of the esophagogastric junction. Surg Endosc. 2018;32(1):383–90.  https://doi.org/10.1007/s00464-017-5687-6. Epub 2017 Jun 27CrossRefPubMedGoogle Scholar
  27. 27.
    Yamashita H, Katai H, Morita S, Saka M, Taniguchi H, Fukagawa T. Optimal extent of lymph node dissection for Siewert type II esophagogastric junction carcinoma. Ann Surg. 2011;254(2):274–80.  https://doi.org/10.1097/SLA.0b013e3182263911.CrossRefPubMedGoogle Scholar
  28. 28.
    Hasegawa S, Yoshikawa T, Rino Y, Oshima T, Aoyama T, Hayashi T, Sato T, Yukawa N, Kameda Y, Sasaki T, Ono H, Tsuchida K, Cho H, Kunisaki C, Masuda M, Tsuburaya A. Priority of lymph node dissection for Siewert type II/III adenocarcinoma of the esophagogastric junction. Ann Surg Oncol. 2013;20(13):4252–9.  https://doi.org/10.1245/s10434-013-3036-0. Epub 2013 Aug 14CrossRefPubMedGoogle Scholar
  29. 29.
    Mine S, Sano T, Hiki N, Yamada K, Nunobe S, Yamaguchi T. Lymphadenectomy around the left renal vein in Siewert type II adenocarcinoma of the oesophagogastric junction. Br J Surg. 2013;100(2):261–6.  https://doi.org/10.1002/bjs.8967. Epub 2012 Nov 23CrossRefPubMedGoogle Scholar
  30. 30.
    Nakamura M, Iwahashi M, Nakamori M, Naka T, Ojima T, Iida T, Katsuda M, Tsuji T, Hayata K, Mastumura S, Yamaue H. Lower mediastinal lymph node metastasis is an independent survival factor of Siewert type II and III adenocarcinomas in the gastroesophageal junction. Am Surg. 2012;78(5):567–73.PubMedGoogle Scholar
  31. 31.
    Lee IS, Ahn JY, Yook JH, Kim BS. Mediastinal lymph node dissection and distal esophagectomy is not essential in early esophagogastric junction adenocarcinoma. World J Surg Oncol. 2017;15(1):28.  https://doi.org/10.1186/s12957-016-1088-x.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Suh YS, Lee KG, Oh SY, Kong SH, Lee HJ, Kim WH, Yang HK. Recurrence pattern and lymph node metastasis of adenocarcinoma at the esophagogastric junction. Ann Surg Oncol. 2017;24(12):3631–9.  https://doi.org/10.1245/s10434-017-6011-3. Epub 2017 Aug 21CrossRefPubMedGoogle Scholar
  33. 33.
    Wang JB, Lin MQ, Li P, Xie JW, Lin JX, Lu J, Chen QY, Cao LL, Lin M, Zheng CH, Huang CM. The prognostic relevance of parapyloric lymph node metastasis in Siewert type II/III adenocarcinoma of the esophagogastric junction. Eur J Surg Oncol. 2017;43(12):2333–40.  https://doi.org/10.1016/j.ejso.2017.08.017. Epub 2017 Sep 8CrossRefPubMedGoogle Scholar
  34. 34.
    Anderegg MC, Lagarde SM, Jagadesham VP, Gisbertz SS, Immanuel A, Meijer SL, Hulshof MC, Bergman JJ, van Laarhoven HW, Griffin SM, van Berge Henegouwen MI. Prognostic significance of the location of lymph node metastases in patients with adenocarcinoma of the distal esophagus or gastroesophageal junction. Ann Surg. 2016;264(5):847–53.CrossRefGoogle Scholar
  35. 35.
    Yamashita H, Seto Y, Sano T, Makuuchi H, Ando N, Sasako M. Japanese gastric cancer association and the Japan esophageal society. Results of a nation-wide retrospective study of lymphadenectomy for esopha-gogastric junction carcinoma. Gastric Cancer. 2017;20(Suppl1):69–83.  https://doi.org/10.1007/s10120-016-0663-8. Epub 2016 Oct 28CrossRefPubMedGoogle Scholar
  36. 36.
    Huh YJ, Lee HJ, Oh SY, Lee KG, Yang JY, Ahn HS, Suh YS, Kong SH, Lee KU, Yang HK. Clinical outcome of modified laparoscopy-assisted proximal gastrectomy compared to conventional proximal gastrectomy or total gastrectomy for upper-third early gastric cancer with special references to postoperative reflux esophagitis. J Gastric Cancer. 2015;15(3):191–200.  https://doi.org/10.5230/jgc.2015.15.3.191. Epub 2015 Sep 30CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Nishigori T, Okabe H, Tsunoda S, Shinohara H, Obama K, Hosogi H, Hisamori S, Miyazaki K, Nakayama T, Sakai Y. Superiority of laparoscopic proximal gastrectomy with hand-sewn esopha-gogastrostomy over total gastrectomy in improving postoperative body weight loss and quality of life. Surg Endosc. 2017;31(9):3664–72.  https://doi.org/10.1007/s00464-016-5403-y. Epub 2017 Jan 11CrossRefPubMedGoogle Scholar
  38. 38.
    Jung DH, Lee Y, Kim DW, Park YS, Ahn SH, Park DJ, Kim HH. Laparoscopic proximal gastrectomy with double tract reconstruction is superior to laparoscopic total gastrectomy for proximal early gastric cancer. Surg Endosc. 2017;31(10):3961–9.  https://doi.org/10.1007/s00464-017-5429-9. Epub 2017 Mar 24CrossRefPubMedGoogle Scholar
  39. 39.
    Sugoor P, Shah S, Dusane R, Desouza A, Goel M, Shrikhande SV. Proximal gastrectomy versus total gastrectomy for proximal third gastric cancer: total gastrectomy is not always necessary. Langenbeck’s Arch Surg. 2016;401(5):687–97.  https://doi.org/10.1007/s00423-016-1422-3. Epub 2016 May 4CrossRefGoogle Scholar
  40. 40.
    Tao K, Dong JH. Phase I clinical research of jejunal interposition in adenocarcinoma of the esophagogastric junction II/III proximal gastrectomy. Gastroenterol Res Pract. 2016;2016:1639654. Epub 2016 Oct 19PubMedPubMedCentralGoogle Scholar
  41. 41.
    Karanicolas PJ, Graham D, Gönen M, Strong VE, Brennan MF, Coit DG. Quality of life after gastrectomy for adenocarcinoma: a prospective cohort study. Ann Surg. 2013;257(6):1039–46.  https://doi.org/10.1097/SLA.0b013e31828c4a19.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Yasuyuki Seto
    • 1
    Email author
  • Hiroharu Yamashita
    • 1
  • Susumu Aikou
    • 1
  1. 1.Department of Gastrointestinal Surgery, Graduate School of MedicineUniversity of TokyoTokyoJapan

Personalised recommendations